| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/31/2013 | WO2013013417A1 Medicament useful for reducing blood sugar and body weight having the structure of stilbene compounds |
| 01/31/2013 | WO2013013351A1 Immediate release-sustained release osmotic pump perparation of compund methoxyphenamine |
| 01/31/2013 | WO2012172433A3 A sustained -release composition containing a melanocortin receptor ligand as the active ingredient |
| 01/31/2013 | WO2012158856A3 Medicaments and methods for treating cancer |
| 01/31/2013 | WO2012149301A3 Tolerogenic synthetic nanocarriers for inducing regulatory b cells |
| 01/31/2013 | WO2012136816A3 Pharmaceutical composition |
| 01/31/2013 | WO2012135562A3 Polymer conjugates targeting cells and methods related thereto |
| 01/31/2013 | WO2012094653A4 Compositions and methods for macromolecular drug delivery |
| 01/31/2013 | WO2011159871A8 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
| 01/31/2013 | US20130030282 Synthesis and characterization of near ir fluorescent magnetic and non-magnetic albumin nanoparticles for biomedical applications |
| 01/31/2013 | US20130030059 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
| 01/31/2013 | US20130030030 Allantoin-containing skin cream |
| 01/31/2013 | US20130029965 Pharmaceutical solid dispersions |
| 01/31/2013 | US20130029956 New method |
| 01/31/2013 | US20130029952 Combination of Azelastine and Mometasone for Nasal Administration |
| 01/31/2013 | US20130029951 Combination of Azelastine and Ciclesonide for Nasal Administration |
| 01/31/2013 | US20130029936 Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same |
| 01/31/2013 | US20130029845 Isoxazolines for controlling invertebrate pests |
| 01/31/2013 | US20130028978 Compositions and methods for wound treatment |
| 01/31/2013 | US20130028977 Pharmaceutical powder composition for inhalation |
| 01/31/2013 | US20130028976 Spray-dried crystalline active ingredient |
| 01/31/2013 | US20130028975 Hemostatic sponge |
| 01/31/2013 | US20130028974 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan |
| 01/31/2013 | US20130028973 Particulate comprising a calcium-containing compound and a sugar alcohol |
| 01/31/2013 | US20130028972 Tamper-resistant tablet providing immediate drug release |
| 01/31/2013 | US20130028971 Pharmaceutical Compositions Comprising Rifaximin, Processes For Their Preparation And Their Use In The Treatment Of Vaginal Infections |
| 01/31/2013 | US20130028970 Tamper-resistant tablet providing immediate drug release |
| 01/31/2013 | US20130028969 Method for stable and controlled delivery of (-)-hydroxycitric acid |
| 01/31/2013 | US20130028968 Compositions and methods to relieve chronic diseases symptoms |
| 01/31/2013 | US20130028967 Therapeutic agent for pulmonary fibrosis |
| 01/31/2013 | US20130028966 Broad Spectrum Antiviral and Antiparasitic Agents |
| 01/31/2013 | US20130028965 NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION |
| 01/31/2013 | US20130028964 NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION |
| 01/31/2013 | US20130028963 Forming an Artificial Cell with controlled membrane composition, asymmetry, and contents |
| 01/31/2013 | US20130028962 Triggered Cargo Release from Nanoparticle Stabilized Liposomes |
| 01/31/2013 | US20130028961 Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
| 01/31/2013 | US20130028960 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
| 01/31/2013 | US20130028959 Liposomes for Preventing the Spread of HIV |
| 01/31/2013 | US20130028958 Beta-carbolines for use in the treatment of hearing loss and vertigo |
| 01/31/2013 | US20130028957 Pharmaceutical composition for treating cancer |
| 01/31/2013 | US20130028956 Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore |
| 01/31/2013 | US20130028955 Sustained release oral matrix and methods of making thereof |
| 01/31/2013 | US20130028953 Transdermal Delivery Systems for Sufentanil |
| 01/31/2013 | US20130028951 Polymer-Liposome Nanocomposite Composition for Percutaneous Absorption, and Method for Preparing Same |
| 01/31/2013 | US20130028947 Pharmaceutical composition for topical application |
| 01/31/2013 | US20130028946 Relating to antiviral compositions |
| 01/31/2013 | US20130028945 Novel composition for treatment of essential thrombocythemia |
| 01/31/2013 | US20130028944 Novel methods for targeting cancer stem cells |
| 01/31/2013 | US20130028943 Melatonin tablet and methods of preparation and use |
| 01/31/2013 | US20130028942 Aerosolized nitrite and nitric oxide-donating compounds and uses thereof |
| 01/31/2013 | US20130028941 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| 01/31/2013 | US20130028940 Caspofungin formulations |
| 01/31/2013 | US20130028939 Chimeric human beta defensins |
| 01/31/2013 | US20130028938 Solid pharmaceutical dosage form |
| 01/31/2013 | US20130028937 Co-crystals of venlafaxine and celecoxib |
| 01/31/2013 | US20130028845 Levalbuterol salt |
| 01/31/2013 | DE102011108762A1 Verpresste feste pharmazeutische Zusammensetzung, umfassend amorphes partikuläres Valsartan als Wirkstoff Compressed solid pharmaceutical composition comprising amorphous particulate valsartan as active ingredient |
| 01/31/2013 | DE102006026060B4 Transdermales Therapeutisches System enthaltend als Wirkstoff Nikotin und Verfahren zur Herstellung solcher Systeme Transdermal therapeutic system containing as active substance nicotine and methods for preparing such systems |
| 01/31/2013 | CA2843431A1 Sandalwood oil and its uses related to skin disorders |
| 01/31/2013 | CA2843267A1 Two part formulation system for ophthalmic delivery |
| 01/31/2013 | CA2843144A1 Functionalized calcium phosphate artificial bone and joint compositions and methods of use and manufacture |
| 01/31/2013 | CA2843138A1 New (trimethoxyphenylamino)pyrimidinyl formulations |
| 01/31/2013 | CA2843065A1 Polyacrylate-based active compound-comprising particles |
| 01/31/2013 | CA2842745A1 Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs) |
| 01/31/2013 | CA2842514A1 Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds |
| 01/31/2013 | CA2841361A1 Composition |
| 01/31/2013 | CA2840727A1 Compositions and methods for the treatment of ocular surface allergies |
| 01/31/2013 | CA2838481A1 Matrix compositions for controlled release of peptide and polypeptide molecules |
| 01/31/2013 | CA2816207A1 Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis |
| 01/30/2013 | EP2551237A2 Method for preparing nano-particles |
| 01/30/2013 | EP2550968A1 Non-surgical removal of localized fat accumulation with a bile salt in conjunction with an analgesic or anti-inflammatory agent |
| 01/30/2013 | EP2550967A1 Compressed chewing gum tablet comprising taste-masking agent |
| 01/30/2013 | EP2550962A2 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof |
| 01/30/2013 | EP2550961A1 Solid preparation |
| 01/30/2013 | EP2550960A1 Solid preparation |
| 01/30/2013 | EP2550959A1 Lisuride, terguride and derivatives of same for use in the prevention and/or treatment of fibrotic changes |
| 01/30/2013 | EP2550958A1 Controlled release formulations of lipocalin muteins |
| 01/30/2013 | EP2550957A1 Effervescent formulations of vildagliptin |
| 01/30/2013 | EP2550945A1 Tampon with a cavity |
| 01/30/2013 | EP2550863A1 Particles on a polyacrylate basis containing active materials |
| 01/30/2013 | EP2550391A1 Process of treatment of fibers and/or textile materials |
| 01/30/2013 | EP2550020A2 Reverse micelle microemulsion comprising metal ions and use thereof |
| 01/30/2013 | EP2550007A1 Desmopressin for reducing nocturnal voids |
| 01/30/2013 | EP2550005A1 Transdermal administration of peptides |
| 01/30/2013 | EP2549994A1 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells |
| 01/30/2013 | EP2549993A2 Antimicrobial compositions |
| 01/30/2013 | EP2549988A1 Fast dissolving drug delivery systems |
| 01/30/2013 | EP2549987A1 Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
| 01/30/2013 | EP2549986A1 Multi-compartmental macrophage delivery |
| 01/30/2013 | EP2549985A1 Stable pharmaceutical compositions comprising fesoterodine |
| 01/30/2013 | EP2549984A1 Double-layer pharmaceutical formulations containing opioid agonists and antagonists |
| 01/30/2013 | EP2549983A2 Novel composition for treatment of essential thrombocythemia |
| 01/30/2013 | EP2549982A1 Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
| 01/30/2013 | EP2549981A1 Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders |
| 01/30/2013 | EP2549980A2 Reverse micelle system comprising nucleic acids and use thereof |
| 01/30/2013 | EP2549877A1 Composition and method for preventing oral disease |
| 01/30/2013 | EP2549867A1 Compositions and methods for prevention and treatment of wounds |
| 01/30/2013 | CN202699645U Musk analgesic rheumatoid plaster |
| 01/30/2013 | CN202699643U Compound tamsulosin-finasteride capsule |
| 01/30/2013 | CN1919328B Chinese medicinal compound formulation of anticancer zanthoxylum and curcuma zedoaria |